

# Hans-Jürgen Müller

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11233107/publications.pdf>

Version: 2024-02-01

556  
papers

45,424  
citations

1371

108  
h-index

3182

186  
g-index

569  
all docs

569  
docs citations

569  
times ranked

34510  
citing authors

#	ARTICLE	IF	CITATIONS
1	Beneficial effects of Silexan on co-occurring depressive symptoms in patients with subthreshold anxiety and anxiety disorders: randomized, placebo-controlled trials revisited. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2023, 273, 51-63.	3.2	4
2	Subsyndromal generalised anxiety disorder: operationalisation and epidemiology – a systematic literature survey. <i>International Journal of Psychiatry in Clinical Practice</i> , 2022, 26, 277-286.	2.4	5
3	Chronic vs non-chronic depression in psychiatric inpatient care - Data from a large naturalistic multicenter trial. <i>Journal of Affective Disorders</i> , 2022, 299, 73-84.	4.1	6
4	The ongoing discussion on termination of life on request. A review from a German/European perspective. <i>International Journal of Psychiatry in Clinical Practice</i> , 2021, 25, 2-18.	2.4	9
5	Silexan does not affect driving performance after single and multiple dose applications: Results from a double-blind, placebo and reference-controlled study in healthy volunteers. <i>Journal of Psychiatric Research</i> , 2021, 136, 543-551.	3.1	4
6	Medication management of antipsychotic treatment in schizophrenia – A narrative review. <i>Human Psychopharmacology</i> , 2021, 36, e2765.	1.5	2
7	No Abuse Potential of Silexan in Healthy Recreational Drug Users: A Randomized Controlled Trial. <i>International Journal of Neuropsychopharmacology</i> , 2021, 24, 171-180.	2.1	6
8	What happens with schizophrenia patients after their discharge from hospital? Results on outcome and treatment from a –real-world–2-year follow-up trial. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2020, 270, 661-671.	3.2	7
9	The place of comorbidity and of subtle psychopathological evaluation. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2020, 270, 939-940.	3.2	0
10	Therapy resistance/chronicity, their determinants and potential solutions. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2020, 270, 1-2.	3.2	11
11	Polymorphisms in CRYBB2 encoding Î²2-crystallin are associated with antisaccade performance and memory function. <i>Translational Psychiatry</i> , 2020, 10, 113.	4.8	3
12	Classification Systems of Mental Disorders: Where Did We Go Wrong?. , 2020, , 193-203.		1
13	Neurocognitive and neuroanatomical maturation in the clinical high-risk states for psychosis: A pattern recognition study. <i>NeuroImage: Clinical</i> , 2019, 21, 101624.	2.7	11
14	Remission in schizophrenia – What are we measuring? Comparing the consensus remission criteria to a CGI-based definition of remission and to remission in major depression. <i>Schizophrenia Research</i> , 2019, 209, 185-192.	2.0	5
15	WFSBP guidelines on how to grade treatment evidence for clinical guideline development. <i>World Journal of Biological Psychiatry</i> , 2019, 20, 2-16.	2.6	26
16	Comparing Schizophrenia Patients With a Predicted High/Low Risk of Nonresponse Receiving Treatment with Ziprasidone and Haloperidol: A Randomized-Controlled Study. <i>Pharmacopsychiatry</i> , 2019, 52, 180-185.	3.3	0
17	Predictors of treatment response to psychological interventions in people at clinical high risk of first-episode psychosis. <i>Microbial Biotechnology</i> , 2019, 13, 120-127.	1.7	5
18	Efficacy of Silexan in subthreshold anxiety: meta-analysis of randomised, placebo-controlled trials. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2019, 269, 183-193.	3.2	37

#	ARTICLE	IF	CITATIONS
19	Stigma experiences and perceived stigma in patients with first-episode schizophrenia in the course of 1 year after their first in-patient treatment. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2019, 269, 459-468.	3.2	19
20	Therapeutic efficacy of the Ginkgo special extract EGb761 within the framework of the mitochondrial cascade hypothesis of Alzheimer's disease. <i>World Journal of Biological Psychiatry</i> , 2019, 20, 173-189.	2.6	45
21	Subtypes of depression and their overlap in a naturalistic inpatient sample of major depressive disorder. <i>International Journal of Methods in Psychiatric Research</i> , 2018, 27, .	2.1	34
22	Silexan in anxiety disorders: Clinical data and pharmacological background. <i>World Journal of Biological Psychiatry</i> , 2018, 19, 412-420.	2.6	96
23	The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Acute and long-term treatment of mixed states in bipolar disorder. <i>World Journal of Biological Psychiatry</i> , 2018, 19, 2-58.	2.6	128
24	A standardized stepwise drug treatment algorithm for depression reduces direct treatment costs in depressed inpatients – Results from the German Algorithm Project (GAP3). <i>Journal of Affective Disorders</i> , 2018, 228, 173-177.	4.1	9
25	Suicidal Ideation and Suicidal Behavior as Rare Adverse Events of Antidepressant Medication: Current Report from the AMSP Multicenter Drug Safety Surveillance Project. <i>International Journal of Neuropsychopharmacology</i> , 2018, 21, 814-821.	2.1	34
26	Is schizophrenia still one entity with similar symptomatic patterns, neurobiological characteristics, and treatment perspectives?. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2018, 268, 525-527.	3.2	2
27	Efficacy of extended clinical management, group CBT, and group plus individual CBT for major depression: Results of a two-year follow-up study. <i>Journal of Affective Disorders</i> , 2018, 238, 570-578.	4.1	6
28	Possibilities and limitations of DSM-5 in improving the classification and diagnosis of mental disorders. <i>Psychiatria Polska</i> , 2018, 52, 611-628.	0.5	9
29	A proposal for a psychopharmacology "pharmacotherapy catalogue of learning objectives and a curriculum in Europe. <i>World Journal of Biological Psychiatry</i> , 2017, 18, 29-38.	2.6	13
30	World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia – a short version for primary care. <i>International Journal of Psychiatry in Clinical Practice</i> , 2017, 21, 82-90.	2.4	61
31	Add-on Antidepressants in the Naturalistic Treatment of Schizophrenia Spectrum Disorder – When, Who, and How?. <i>Pharmacopsychiatry</i> , 2017, 50, 136-144.	3.3	3
32	Associations of NEUROD2 polymorphisms and change of cognitive dysfunctions in schizophrenia and schizoaffective disorder after eight weeks of antipsychotic treatment. <i>Cognitive Neuropsychiatry</i> , 2017, 22, 280-297.	1.3	14
33	Why are new antidepressants failing to make the grade for approval?. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 641-643.	1.8	2
34	Pharmacological treatment of unipolar depressive disorders: summary of WFSBP guidelines. <i>International Journal of Psychiatry in Clinical Practice</i> , 2017, 21, 166-176.	2.4	115
35	Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology. <i>American Journal of Psychiatry</i> , 2017, 174, 216-229.	7.2	685
36	Guidelines for biological treatment of substance use and related disorders, part 1: Alcoholism, first revision. <i>World Journal of Biological Psychiatry</i> , 2017, 18, 86-119.	2.6	55

#	ARTICLE	IF	CITATIONS
37	New aspects of the vulnerability stress model in general, its relevance in schizophrenic psychoses and the place of antipsychotics. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2017, 267, 485-486.	3.2	1
38	How Effective Is Algorithm-Guided Treatment for Depressed Inpatients? Results from the Randomized Controlled Multicenter German Algorithm Project 3 Trial. <i>International Journal of Neuropsychopharmacology</i> , 2017, 20, 721-730.	2.1	44
39	Validity of remission and recovery criteria for schizophrenia and major depression: comparison of the results of two one-year follow-up naturalistic studies. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2017, 267, 303-313.	3.2	8
40	Silexan in generalized anxiety disorder. <i>International Clinical Psychopharmacology</i> , 2017, 32, 195-204.	1.7	19
41	Psychiatrie, Psychosomatik, Psychotherapie – Bedeutung, Identität, Situation und Perspektiven eines großen medizinischen Fachgebietes. , 2017, , 3-37.		0
42	Evidenzbasierung und leitliniengestützte Therapie in der Psychiatrie. , 2017, , 1321-1338.		0
43	Psychopharmakotherapie – klinisch-empirische Grundlagen. , 2017, , 795-842.		1
44	Prinzipien der Methodik empirischer Forschung in der Psychiatrie. , 2017, , 463-490.		0
45	Standardisierte Befunddiagnostik in der Psychiatrie. , 2017, , 577-600.		0
46	Challenging the understanding of significant improvement and outcome in schizophrenia – the concept of reliable and clinically significant change methods. <i>International Journal of Methods in Psychiatric Research</i> , 2016, 25, 3-11.	2.1	5
47	The relevance of “mixed anxiety and depression” as a diagnostic category in clinical practice. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2016, 266, 725-736.	3.2	82
48	Neuroscience-based nomenclature (jNbn) to replace traditional terminology of psychotropic medications. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2016, 266, 385-386.	3.2	7
49	Psychoeducational and Cognitive Behavioral Treatment Programs: Implementation and Evaluation From 1995 to 2015 in Kraepelin’s Former Hospital. <i>Schizophrenia Bulletin</i> , 2016, 42, S81-S89.	4.3	7
50	A Randomized Controlled Trial of Group Coping-Oriented Therapy vs Supportive Therapy in Schizophrenia: Results of a 2-Year Follow-up. <i>Schizophrenia Bulletin</i> , 2016, 42, S71-S80.	4.3	19
51	Stability of remission rates in a 3-year follow-up of naturalistic treated depressed inpatients. <i>BMC Psychiatry</i> , 2016, 16, 153.	2.6	7
52	Coping as a predictor of treatment outcome in people at clinical high risk of psychosis. <i>Microbial Biotechnology</i> , 2016, 10, 17-27.	1.7	19
53	Mobility behaviour and driving status of patients with mental disorders – an exploratory study. <i>International Journal of Psychiatry in Clinical Practice</i> , 2016, 20, 40-46.	2.4	20
54	The FKBP5 polymorphism rs1360780 influences the effect of an algorithm-based antidepressant treatment and is associated with remission in patients with major depression. <i>Journal of Psychopharmacology</i> , 2016, 30, 40-47.	4.0	34

#	ARTICLE	IF	CITATIONS
55	Effects of rivastigmine on visual attention in subjects with amnesic mild cognitive impairment: A serial functional MRI activation pilot-study. <i>Psychiatry Research - Neuroimaging</i> , 2016, 249, 84-90.	1.8	10
56	Predictors for symptom re-exacerbation after targeted stepwise drug discontinuation in first-episode schizophrenia. <i>Schizophrenia Research</i> , 2016, 170, 168-176.	2.0	34
57	EEG correlates of visual short-term memory as neuro-cognitive endophenotypes of ADHD. <i>Neuropsychologia</i> , 2016, 85, 91-99.	1.6	27
58	Prediction of outcome in the psychosis prodrome using neuroanatomical pattern classification. <i>Schizophrenia Research</i> , 2016, 173, 159-165.	2.0	50
59	Evidenzbasierung und leitliniengestützte Therapie in der Psychiatrie. , 2016, , 1-18.		0
60	Psychiatrie, Psychosomatik, Psychotherapie – Bedeutung, Identität, Situation und Perspektiven eines großen medizinischen Fachgebietes. , 2016, , 1-35.		1
61	The Relevance of Negative Symptoms in Schizophrenia and How to Treat Them with Psychopharmaceuticals?. <i>Psychiatria Danubina</i> , 2016, 28, 435-440.	0.4	10
62	Obsessive-compulsive disorder – A question of conscience? An fMRI study of behavioural and neurofunctional correlates of shame and guilt. <i>Journal of Psychiatric Research</i> , 2015, 68, 354-362.	3.1	22
63	Early Improvement As a Predictor of Later Response to Antipsychotics in Schizophrenia: A Diagnostic Test Review. <i>American Journal of Psychiatry</i> , 2015, 172, 617-629.	7.2	150
64	Report of the WPA section of pharmacopsychiatry on the relationship of antiepileptic drugs with suicidality in epilepsy. <i>International Journal of Psychiatry in Clinical Practice</i> , 2015, 19, 158-167.	2.4	24
65	The Speed of Visual Attention and Motor-Response Decisions in Adult Attention-Deficit/Hyperactivity Disorder. <i>Biological Psychiatry</i> , 2015, 78, 107-115.	1.3	36
66	What are residual symptoms in schizophrenia spectrum disorder? Clinical description and 1-year persistence within a naturalistic trial. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2015, 265, 107-116.	3.2	26
67	World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders. Part 2: Maintenance Treatment of Major Depressive Disorder-Update 2015. <i>World Journal of Biological Psychiatry</i> , 2015, 16, 76-95.	2.6	153
68	Characteristics and differences in treatment outcome of inpatients with chronic vs. episodic major depressive disorders. <i>Journal of Affective Disorders</i> , 2015, 173, 126-133.	4.1	22
69	Pharmacological treatment of negative symptoms in schizophrenia. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2015, 265, 567-578.	3.2	55
70	DSM-5 reviewed from different angles: goal attainment, rationality, use of evidence, consequences – part 1: general aspects and paradigmatic discussion of depressive disorders. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2015, 265, 5-18.	3.2	23
71	Biomarkers for Psychiatry: The Journey from Fantasy to Fact, a Report of the 2013 CINP Think Tank: Figure 1.. <i>International Journal of Neuropsychopharmacology</i> , 2015, 18, pyv042.	2.1	84
72	Individualized differential diagnosis of schizophrenia and mood disorders using neuroanatomical biomarkers. <i>Brain</i> , 2015, 138, 2059-2073.	7.6	132

#	ARTICLE	IF	CITATIONS
73	World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia Part 3: Update 2015 Management of special circumstances: Depression, Suicidality, substance use disorders and pregnancy and lactation. World Journal of Biological Psychiatry, 2015, 16, 142-170.	2.6	106
74	Two Phase III randomised double-blind studies of fixed-dose TC-5214 (dexmecamylamine) adjunct to ongoing antidepressant therapy in patients with major depressive disorder and an inadequate response to prior antidepressant therapy. World Journal of Biological Psychiatry, 2015, 16, 483-501.	2.6	26
75	A review of the current nomenclature for psychotropic agents and an introduction to the Neuroscience-based Nomenclature. European Neuropsychopharmacology, 2015, 25, 2318-2325.	0.7	135
76	DSM-5 reviewed from different angles: goal attainment, rationality, use of evidence, consequences" part 2: bipolar disorders, schizophrenia spectrum disorders, anxiety disorders, obsessive-compulsive disorders, trauma- and stressor-related disorders, personality disorders, substance-related and addictive disorders, neurocognitive disorders. European Archives of Psychiatry and Clinical Neuroscience, 2015, 265, 87-106.	3.2	26
77	World Federation of Societies of Biological Psychiatry guidelines for the pharmacological treatment of dementias in primary care. International Journal of Psychiatry in Clinical Practice, 2015, 19, 2-7.	2.4	23
78	Prinzipien der Methodik empirischer Forschung in der Psychiatrie. , 2015, , 1-28.		0
79	Standardisierte Befunddiagnostik in der Psychiatrie. , 2015, , 1-25.		0
80	Psychiatric Assessment: Negative Symptoms. , 2015, , 290-294.		0
81	Are antidepressants clinically useful? Conclusion of a decade of debate. World Psychiatry, 2014, 13, 201-202.	10.4	7
82	Pleckstrin homology domain containing 6 protein (PLEKHA6) polymorphisms are associated with psychopathology and response to treatment in schizophrenic patients. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2014, 51, 190-195.	4.8	10
83	A proposal for an updated neuropsychopharmacological nomenclature. European Neuropsychopharmacology, 2014, 24, 1005-1014.	0.7	83
84	Three-Year long-term outcome of 458 naturalistically treated inpatients with major depressive episode: severe relapse rates and risk factors. European Archives of Psychiatry and Clinical Neuroscience, 2014, 264, 567-575.	3.2	38
85	Rates and predictors of remission in first-episode schizophrenia within 1 year of antipsychotic maintenance treatment. Results of a randomized controlled trial within the German Research Network on Schizophrenia. Schizophrenia Research, 2014, 152, 478-486.	2.0	33
86	Lavender oil preparation Silexan is effective in generalized anxiety disorder " a randomized, double-blind comparison to placebo and paroxetine. International Journal of Neuropsychopharmacology, 2014, 17, 859-869.	2.1	161
87	Accelerated Brain Aging in Schizophrenia and Beyond: A Neuroanatomical Marker of Psychiatric Disorders. Schizophrenia Bulletin, 2014, 40, 1140-1153.	4.3	369
88	The consequences of DSM-5 for psychiatric diagnosis and psychopharmacotherapy. International Journal of Psychiatry in Clinical Practice, 2014, 18, 78-85.	2.4	12
89	The effects of methylphenidate on whole brain intrinsic functional connectivity. Human Brain Mapping, 2014, 35, 5379-5388.	3.6	74
90	The media and intellectuals' response to medical publications: the anti-depressants' case. Annals of General Psychiatry, 2013, 12, 11.	2.7	16

#	ARTICLE	IF	CITATIONS
91	No influence of brain-derived neurotrophic factor (BDNF) polymorphisms on treatment response in a naturalistic sample of patients with major depression. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2013, 263, 405-412.	3.2	18
92	Association between psychopathology and problems of psychosocial functioning in the long-term outcome of patients diagnosed with schizophrenic, schizoaffective and affective disorders. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2013, 263, 85-92.	3.2	20
93	Neuropsychological functioning in inpatients with major depression or schizophrenia. <i>BMC Psychiatry</i> , 2013, 13, 203.	2.6	18
94	No role for initial severity on the efficacy of antidepressants: results of a multi-meta-analysis. <i>Annals of General Psychiatry</i> , 2013, 12, 26.	2.7	62
95	The best next drug in the course of generalized anxiety disorders: the "PN-GAD-algorithm". <i>International Journal of Psychiatry in Clinical Practice</i> , 2013, 17, 78-89.	2.4	8
96	Influence of ANKK1 and DRD2 polymorphisms in response to haloperidol. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2013, 263, 65-74.	3.2	16
97	AKAP13, CACNA1, GRIK4 and GRIA1 genetic variations may be associated with haloperidol efficacy during acute treatment. <i>European Neuropsychopharmacology</i> , 2013, 23, 887-894.	0.7	27
98	Interference control in adult ADHD: No evidence for interference control deficits if response speed is controlled by delta plots. <i>Acta Psychologica</i> , 2013, 143, 71-78.	1.5	11
99	Genetics of emergent suicidality during antidepressive treatment"Data from a naturalistic study on a large sample of inpatients with a major depressive episode. <i>European Neuropsychopharmacology</i> , 2013, 23, 663-674.	0.7	21
100	The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2012 on the long-term treatment of bipolar disorder. <i>World Journal of Biological Psychiatry</i> , 2013, 14, 154-219.	2.6	344
101	World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 2: Update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. <i>World Journal of Biological Psychiatry</i> , 2013, 14, 2-44.	2.6	343
102	Impulsivity is related to striatal dopamine transporter availability in healthy males. <i>Psychiatry Research - Neuroimaging</i> , 2013, 211, 251-256.	1.8	33
103	Reliability and plasticity of response inhibition and interference control. <i>Brain and Cognition</i> , 2013, 81, 82-94.	1.8	162
104	Intact emotion-cognition interaction in schizophrenia patients and first-degree relatives: Evidence from an emotional antisaccade task. <i>Brain and Cognition</i> , 2013, 82, 329-336.	1.8	16
105	World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Update 2013 on the acute and continuation treatment of unipolar depressive disorders. <i>World Journal of Biological Psychiatry</i> , 2013, 14, 334-385.	2.6	480
106	The potential role of Marginal Structural Models (MSMs) in testing the effectiveness of antidepressants in the treatment of patients with major depression in everyday clinical practice. <i>World Journal of Biological Psychiatry</i> , 2013, 14, 386-395.	2.6	4
107	Methylphenidate Effects on Neural Activity During Response Inhibition in Healthy Humans. <i>Cerebral Cortex</i> , 2013, 23, 1179-1189.	2.9	55
108	Brain-derived neurotrophic factor Val66Met polymorphism and early life adversity affect hippocampal volume. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2013, 162, 183-190.	1.7	85

#	ARTICLE	IF	CITATIONS
109	Repeated Ketamine Infusions in Therapy Resistant Depression: A Case Series. <i>Journal of Clinical Pharmacology</i> , 2013, 53, 996-998.	2.0	57
110	Driving Ability According to German Guidelines in Stabilized Bipolar I and II Outpatients Receiving Lithium or Lamotrigine. <i>Journal of Clinical Pharmacology</i> , 2013, 53, 459-462.	2.0	9
111	The Diagnosis and Treatment of Generalized Anxiety Disorder. <i>Deutsches Ärzteblatt International</i> , 2013, 110, 300-9; quiz 310.	0.9	47
112	Glutamatergic Dysbalance and Oxidative Stress in In Vivo and In Vitro Models of Psychosis Based on Chronic NMDA Receptor Antagonism. <i>PLoS ONE</i> , 2013, 8, e59395.	2.5	24
113	Antipsychotic Treatment Within a Naturalistic Trial – How Are We Treating Schizophrenia Patients in the “Real-World”. , 2013, , 137-156.		0
114	In Reply. <i>Deutsches Ärzteblatt International</i> , 2013, 110, 610-1.	0.9	0
115	Early Recognition and Disease Prediction in the At-Risk Mental States for Psychosis Using Neurocognitive Pattern Classification. <i>Schizophrenia Bulletin</i> , 2012, 38, 1200-1215.	4.3	121
116	Infectious agents are associated with psychiatric diseases. <i>Mental Illness</i> , 2012, 4, 38-42.	0.8	9
117	Antidepressant drugs and the response in the placebo group: the real problem lies in our understanding of the issue. <i>Journal of Psychopharmacology</i> , 2012, 26, 744-750.	4.0	24
118	Akathisia and Suicidal Ideation in First-Episode Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2012, 32, 694-698.	1.4	29
119	Predictors of Relapse in the Year After Hospital Discharge Among Patients With Schizophrenia. <i>Psychiatric Services</i> , 2012, 63, 87-90.	2.0	79
120	Evaluating Depressive Symptoms in Schizophrenia: A Psychometric Comparison of the Calgary Depression Scale for Schizophrenia and the Hamilton Depression Rating Scale. <i>Psychopathology</i> , 2012, 45, 276-285.	1.5	46
121	Disease Prediction in the At-Risk Mental State for Psychosis Using Neuroanatomical Biomarkers: Results From the FePsy Study. <i>Schizophrenia Bulletin</i> , 2012, 38, 1234-1246.	4.3	139
122	Depressive symptoms and their association with acute treatment outcome in first-episode schizophrenia patients: Comparing treatment with risperidone and haloperidol. <i>World Journal of Biological Psychiatry</i> , 2012, 13, 30-38.	2.6	23
123	Association between brain structure and psychometric schizotypy in healthy individuals. <i>World Journal of Biological Psychiatry</i> , 2012, 13, 544-549.	2.6	54
124	Antipsychotic Response in the First Week Predicts Later Efficacy. <i>Neuropsychobiology</i> , 2012, 66, 100-105.	1.9	14
125	Pharmacotherapy of Schizophrenic Patients: Achievements, Unsolved Needs, Future Research Necessities. <i>Current Pharmaceutical Biotechnology</i> , 2012, 13, 1476-1489.	1.6	3
126	State of the Art: Treatment of Bipolar Disorders. <i>CNS Neuroscience and Therapeutics</i> , 2012, 18, 214-218.	3.9	22



#	ARTICLE	IF	CITATIONS
127	One-year functional outcomes of naturalistically treated patients with schizophrenia. <i>Psychiatry Research</i> , 2012, 198, 378-385.	3.3	34
128	Dysequilibrium of neuronal proliferation and apoptosis in a pharmacological animal model of psychosis. <i>Methods</i> , 2012, 56, 519-527.	3.8	11
129	Study design features affecting outcome in antidepressant trials. <i>Journal of Affective Disorders</i> , 2012, 141, 160-167.	4.1	8
130	Mirroring everyday clinical practice in clinical trial design: a new concept to improve the external validity of randomized double-blind placebo-controlled trials in the pharmacological treatment of major depression. <i>BMC Medicine</i> , 2012, 10, 67.	5.5	11
131	Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care. <i>International Journal of Psychiatry in Clinical Practice</i> , 2012, 16, 77-84.	2.4	327
132	Response trajectories in "real-world" naturalistically treated schizophrenia patients. <i>Schizophrenia Research</i> , 2012, 139, 218-224.	2.0	26
133	Associations between trait impulsivity and prepotent response inhibition. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2012, 34, 1016-1032.	1.3	124
134	World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 1: Update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. <i>World Journal of Biological Psychiatry</i> , 2012, 13, 318-378.	2.6	498
135	Schizotypy and Behavioural Adjustment and the Role of Neuroticism. <i>PLoS ONE</i> , 2012, 7, e30078.	2.5	16
136	Treatment Response in First-episode Schizophrenia. <i>Clinical Psychopharmacology and Neuroscience</i> , 2012, 10, 78-87.	2.0	47
137	Multivariate patterns of brain-cognition associations relating to vulnerability and clinical outcome in the at-risk mental states for psychosis. <i>Human Brain Mapping</i> , 2012, 33, 2104-2124.	3.6	23
138	Remission and Recovery and their Predictors in Schizophrenia Spectrum Disorder: Results from a 1-Year Follow-Up Naturalistic Trial. <i>Psychiatric Quarterly</i> , 2012, 83, 187-207.	2.1	19
139	Functional Outcomes in Schizophrenia: Employment Status as a Metric of Treatment Outcome. <i>Current Psychiatry Reports</i> , 2012, 14, 229-236.	4.5	27
140	Exploring the structure of psychopathological symptoms: a re-analysis of AMDP data by robust nonmetric multidimensional scaling. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2012, 262, 227-238.	3.2	15
141	How close is evidence to truth in evidence-based treatment of mental disorders?. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2012, 262, 277-289.	3.2	7
142	Psychopathology: genetics and the stress-vulnerability hypothesis. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2012, 262, 181-182.	3.2	5
143	Efficacy of pharmacotherapy in bipolar disorder: a report by the WPA section on pharmacopsychiatry. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2012, 262, 1-48.	3.2	113
144	From pathophysiological aspects towards unravelling the neurobiological background of cognitive deficits. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2012, 262, 275-276.	3.2	0

#	ARTICLE	IF	CITATIONS
145	Functional neural correlates of psychometric schizotypy: An fMRI study of antisaccades. <i>Psychophysiology</i> , 2012, 49, 345-356.	2.4	49
146	Critical trial-related criteria in acute schizophrenia studies. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2012, 262, 151-155.	3.2	6
147	Subjective emotional over-arousal to neutral social scenes in paranoid schizophrenia. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2012, 262, 59-68.	3.2	34
148	Executive summary of the report by the WPA section on pharmacopsychiatry on general and comparative efficacy and effectiveness of antidepressants in the acute treatment of depressive disorders. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2012, 262, 13-22.	3.2	21
149	No Association of a Set of Candidate Genes on Haloperidol Side Effects. <i>PLoS ONE</i> , 2012, 7, e44853.	2.5	7
150	Psychiatrie in Europa: Stand der Dinge, Chancen und Herausforderungen. , 2012, , 219-227.		0
151	World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Alzheimer's disease and other dementias. <i>World Journal of Biological Psychiatry</i> , 2011, 12, 2-32.	2.6	77
152	Neuropsychological Profiles in Different At-Risk States of Psychosis: Executive Control Impairment in the Early and Additional Memory Dysfunction in the Late Prodromal State. <i>Schizophrenia Bulletin</i> , 2011, 37, 861-873.	4.3	124
153	A neuropsychological investigation of the genome wide associated schizophrenia risk variant NRCN rs12807809. <i>Schizophrenia Research</i> , 2011, 125, 304-306.	2.0	23
154	Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level. <i>World Psychiatry</i> , 2011, 10, 138-151.	10.4	631
155	Is evaluation of humorous stimuli associated with frontal cortex morphology? A pilot study using facial micro-movement analysis and MRI. <i>Cortex</i> , 2011, 47, 569-574.	2.4	17
156	Sociodemographic and treatment related variables are poor predictors of haloperidol induced motor side effects. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2011, 35, 74-77.	4.8	6
157	Predictors of response and remission in the acute treatment of first-episode schizophrenia patients – Is it all about early response?. <i>European Neuropsychopharmacology</i> , 2011, 21, 370-378.	0.7	46
158	Effectiveness of Quetiapine in Outpatients With Schizophrenia Assessed Under "Real-Life" Conditions. <i>Journal of Clinical Psychopharmacology</i> , 2011, 31, 120-122.	1.4	1
159	Efficacy of antidepressants: a re-analysis and re-interpretation of the Kirsch data. <i>International Journal of Neuropsychopharmacology</i> , 2011, 14, 405-412.	2.1	120
160	Antidepressants vs. placebo: not merely a quantitative difference in response. <i>International Journal of Neuropsychopharmacology</i> , 2011, 14, 1435-1437.	2.1	6
161	Reception of Kraepelin's ideas 1900–1960. <i>Psychiatry and Clinical Neurosciences</i> , 2011, 65, 318-325.	1.8	20
162	Homer-1 polymorphisms are associated with psychopathology and response to treatment in schizophrenic patients. <i>Journal of Psychiatric Research</i> , 2011, 45, 234-241.	3.1	55

#	ARTICLE	IF	CITATIONS
163	Catechol-o-methyltransferase gene modulation on suicidal behavior and personality traits: review, meta-analysis and association study. <i>Journal of Psychiatric Research</i> , 2011, 45, 309-321.	3.1	133
164	Alterations of the early auditory evoked gamma-band response in first-degree relatives of patients with schizophrenia: Hints to a new intermediate phenotype. <i>Journal of Psychiatric Research</i> , 2011, 45, 699-705.	3.1	57
165	Influencing factors and predictors of early improvement in the acute treatment of schizophrenia and schizophrenia spectrum disorder. <i>Journal of Psychiatric Research</i> , 2011, 45, 1639-1647.	3.1	22
166	Clinical predictors of response and remission in inpatients with depressive syndromes. <i>Journal of Affective Disorders</i> , 2011, 133, 137-149.	4.1	71
167	Combining the categorical and the dimensional perspective in a diagnostic map of psychotic disorders. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2011, 261, 3-10.	3.2	17
168	Attention to emotion: auditory-evoked potentials in an emotional choice reaction task and personality traits as assessed by the NEO FFI. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2011, 261, 111-120.	3.2	17
169	General and comparative efficacy and effectiveness of antidepressants in the acute treatment of depressive disorders: a report by the WPA section of pharmacopsychiatry. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2011, 261, 207-245.	3.2	40
170	Lack of association between 71 variations located in candidate genes and response to acute haloperidol treatment. <i>Psychopharmacology</i> , 2011, 214, 719-728.	3.1	2
171	Functional magnetic resonance imaging of a parametric working memory task in schizophrenia: relationship with performance and effects of antipsychotic treatment. <i>Psychopharmacology</i> , 2011, 216, 17-27.	3.1	39
172	Is the PANSS used correctly? a systematic review. <i>BMC Psychiatry</i> , 2011, 11, 113.	2.6	63
173	The cholinergic system in mild cognitive impairment and Alzheimer's disease: An in vivo MRI and DTI study. <i>Human Brain Mapping</i> , 2011, 32, 1349-1362.	3.6	136
174	Maternally Derived Microduplications at 15q11-q13: Implication of Imprinted Genes in Psychotic Illness. <i>American Journal of Psychiatry</i> , 2011, 168, 408-417.	7.2	95
175	Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. <i>World Psychiatry</i> , 2011, 10, 52-77.	10.4	1,767
176	NCAM1, TACR1 and NOS Genes and Temperament: A Study on Suicide Attempters and Controls. <i>Neuropsychobiology</i> , 2011, 64, 32-37.	1.9	12
177	Novel Schizophrenia Risk Gene TCF4 Influences Verbal Learning and Memory Functioning in Schizophrenia Patients. <i>Neuropsychobiology</i> , 2011, 63, 131-136.	1.9	40
178	The Schizophrenia Risk Allele C of the <i>TCF4</i> rs9960767 Polymorphism Disrupts Sensorimotor Gating in Schizophrenia Spectrum and Healthy Volunteers. <i>Journal of Neuroscience</i> , 2011, 31, 6684-6691.	3.6	85
179	The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2010 on the Treatment of Acute Bipolar Depression. <i>Focus (American Psychiatric Publishing)</i> , 2011, 9, 500-525.	0.8	1
180	Disentangling the adult attention-deficit hyperactivity disorder endophenotype: Parametric measurement of attention.. <i>Journal of Abnormal Psychology</i> , 2011, 120, 890-901.	1.9	29

#	ARTICLE	IF	CITATIONS
181	The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Substance Use and Related Disorders. Part 2: Opioid dependence. World Journal of Biological Psychiatry, 2011, 12, 160-187.	2.6	88
182	Effectiveness studies: advantages and disadvantages. Dialogues in Clinical Neuroscience, 2011, 13, 199-207.	3.7	52
183	Relapse Prevention in First-Episode Schizophrenia – Maintenance vs Intermittent Drug Treatment With Prodrome-Based Early Intervention. Journal of Clinical Psychiatry, 2011, 72, 205-218.	2.2	79
184	Biological Perspectives on Psychiatry for the Person. International Journal of Person Centered Medicine, 2011, 1, 137-139.	0.2	15
185	Early Improvement and Its Predictive Validity in First-Episode Schizophrenia Patients. , 2011, , 93-107.		0
186	Suicidality and Outcome in Schizophrenia Patients. , 2011, , 365-382.		0
187	Agomelatine: The evidence for its place in the treatment of depression. Core Evidence, 2010, 4, 171.	4.7	24
188	Does Clinical Judgment of Baseline Severity and Changes in Psychopathology Depend on the Patient Population?. Journal of Clinical Psychopharmacology, 2010, 30, 726-731.	1.4	24
189	Silexan, an orally administered Lavandula oil preparation, is effective in the treatment of “subsyndromal” anxiety disorder: a randomized, double-blind, placebo controlled trial. International Clinical Psychopharmacology, 2010, 25, 277-287.	1.7	126
190	An early improvement threshold to predict response and remission in first-episode schizophrenia. British Journal of Psychiatry, 2010, 196, 460-466.	2.8	42
191	Altered Brain Activation During a Verbal Working Memory Task in Subjects with Amnesic Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2010, 21, 103-118.	2.6	86
192	Differences in hippocampal volume between major depression and schizophrenia: a comparative neuroimaging study. European Archives of Psychiatry and Clinical Neuroscience, 2010, 260, 127-137.	3.2	53
193	Meta-analyses: a method to maximise the evidence from clinical studies?. European Archives of Psychiatry and Clinical Neuroscience, 2010, 260, 17-23.	3.2	17
194	Evidence-based medicine in psychopharmacotherapy: possibilities, problems and limitations. European Archives of Psychiatry and Clinical Neuroscience, 2010, 260, 25-39.	3.2	33
195	Principle standards and problems regarding proof of efficacy in clinical psychopharmacology. European Archives of Psychiatry and Clinical Neuroscience, 2010, 260, 3-16.	3.2	27
196	The Munich 15-year follow-up study (MUFUSSAD) on first-hospitalized patients with schizophrenic or affective disorders: comparison of psychopathological and psychosocial course and outcome and prediction of chronicity. European Archives of Psychiatry and Clinical Neuroscience, 2010, 260, 367-384.	3.2	56
197	Efficacy and safety of silexan, a new, orally administered lavender oil preparation, in subthreshold anxiety disorder – evidence from clinical trials. Wiener Medizinische Wochenschrift, 2010, 160, 547-556.	1.1	51
198	Interaction of haloperidol plasma level and antipsychotic effect in early phases of acute psychosis treatment. Journal of Psychiatric Research, 2010, 44, 487-492.	3.1	23

#	ARTICLE	IF	CITATIONS
199	Response and remission criteria in major depression – A validation of current practice. <i>Journal of Psychiatric Research</i> , 2010, 44, 1063-1068.	3.1	219
200	Anterior cingulum volumetry, auditory P300 in schizophrenia with negative symptoms. <i>Psychiatry Research - Neuroimaging</i> , 2010, 183, 133-139.	1.8	14
201	The need for efficient long-term neuroleptic treatment in schizophrenic patients and the place of long acting injectable antipsychotics. <i>Annals of General Psychiatry</i> , 2010, 9, .	2.7	0
202	Should the PANSS Be Rescaled?. <i>Schizophrenia Bulletin</i> , 2010, 36, 455-460.	4.3	94
203	Quality of life and subjective well-being in schizophrenia and schizophrenia spectrum disorders: Valid predictors of symptomatic response and remission?. <i>World Journal of Biological Psychiatry</i> , 2010, 11, 729-738.	2.6	27
204	A large replication study and meta-analysis in European samples provides further support for association of AHI1 markers with schizophrenia. <i>Human Molecular Genetics</i> , 2010, 19, 1379-1386.	2.9	51
205	Psychosis Susceptibility Gene ZNF804A and Cognitive Performance in Schizophrenia. <i>Archives of General Psychiatry</i> , 2010, 67, 692.	12.3	129
206	Review: antidepressants associated with increased risk of suicidality in adults aged less than 25 years. <i>Evidence-Based Mental Health</i> , 2010, 13, 52-52.	4.5	3
207	The influence of anaesthetic medication on safety, tolerability and clinical effectiveness of electroconvulsive therapy. <i>World Journal of Biological Psychiatry</i> , 2010, 11, 447-456.	2.6	16
208	Orbitofrontal volume reductions during emotion recognition in patients with major depression. <i>Journal of Psychiatry and Neuroscience</i> , 2010, 35, 311-320.	2.4	101
209	Safety evaluation of zotepine for the treatment of schizophrenia. <i>Expert Opinion on Drug Safety</i> , 2010, 9, 659-666.	2.4	2
210	The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2010 on the treatment of acute bipolar depression. <i>World Journal of Biological Psychiatry</i> , 2010, 11, 81-109.	2.6	322
211	Childhood Stress, Serotonin Transporter Gene and Brain Structures in Major Depression. <i>Neuropsychopharmacology</i> , 2010, 35, 1383-1390.	5.4	175
212	Reduced Early Auditory Evoked Gamma-Band Response in Patients with Schizophrenia. <i>Biological Psychiatry</i> , 2010, 67, 224-231.	1.3	110
213	Functional Connectivity Bias of the Orbitofrontal Cortex in Drug-Free Patients with Major Depression. <i>Biological Psychiatry</i> , 2010, 67, 161-167.	1.3	164
214	Social disability in schizophrenic, schizoaffective and affective disorders 15years after first admission. <i>Schizophrenia Research</i> , 2010, 116, 9-15.	2.0	73
215	Neuroanatomical correlates of executive dysfunction in the at-risk mental state for psychosis. <i>Schizophrenia Research</i> , 2010, 123, 160-174.	2.0	46
216	Use of neuroanatomical pattern regression to predict the structural brain dynamics of vulnerability and transition to psychosis. <i>Schizophrenia Research</i> , 2010, 123, 175-187.	2.0	58

#	ARTICLE	IF	CITATIONS
217	Influence of neuronal cell adhesion molecule (NCAM1) variants on suicidal behaviour and correlated traits. <i>Psychiatry Research</i> , 2010, 179, 222-225.	3.3	10
218	Outcomes of 1014 naturalistically treated inpatients with major depressive episode. <i>European Neuropsychopharmacology</i> , 2010, 20, 346-355.	0.7	72
219	Celecoxib treatment in an early stage of schizophrenia: Results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment. <i>Schizophrenia Research</i> , 2010, 121, 118-124.	2.0	227
220	White matter microstructure underlying default mode network connectivity in the human brain. <i>NeuroImage</i> , 2010, 49, 2021-2032.	4.2	185
221	Long-acting atypical injectable antipsychotics in the treatment of schizophrenia: safety and tolerability review. <i>Expert Opinion on Drug Safety</i> , 2010, 9, 683-697.	2.4	32
222	Longitudinal analysis of the suicidal behaviour risk in short-term placebo-controlled studies of mirtazapine in major depressive disorder. <i>World Journal of Biological Psychiatry</i> , 2010, 11, 36-44.	2.6	27
223	Is the Overlap of Neurobiological and Psychopathological Parameters: Large Enough to Give up the Dichotomic Classification?. <i>Psychiatric Annals</i> , 2010, 40, 163-167.	0.1	4
224	Do Efficacy and Effectiveness Samples Differ in Antidepressant Treatment Outcome?. <i>Journal of Clinical Psychiatry</i> , 2010, 71, 1425-1433.	2.2	19
225	Suicidality as Rare Adverse Event of Antidepressant Medication. <i>Journal of Clinical Psychiatry</i> , 2010, 71, 1239-1307.	2.2	35
226	Der besondere Stellenwert von Antipsychotika der zweiten Generation in der Therapie schizophrener und affektiver Psychosen. , 2010, , 187-196.		0
227	Neuronal correlates of emotional processing in patients with major depression. <i>World Journal of Biological Psychiatry</i> , 2009, 10, 202-208.	2.6	81
228	Do "real world" studies on antipsychotics tell us the real truth?. <i>World Psychiatry</i> , 2009, 8, 32-32.	10.4	0
229	Tyrosine Hydroxylase and DOPA Decarboxylase Gene Variants in Personality Traits. <i>Neuropsychobiology</i> , 2009, 59, 23-27.	1.9	7
230	The controversial link between antidepressants and suicidality risks in adults: data from a naturalistic study on a large sample of in-patients with a major depressive episode. <i>International Journal of Neuropsychopharmacology</i> , 2009, 12, 181.	2.1	43
231	Neuroanatomical correlates of different vulnerability states for psychosis and their clinical outcomes. <i>British Journal of Psychiatry</i> , 2009, 195, 218-226.	2.8	85
232	Influence of NOS1 on Verbal Intelligence and Working Memory in Both Patients With Schizophrenia and Healthy Control Subjects. <i>Archives of General Psychiatry</i> , 2009, 66, 1045.	12.3	45
233	A Genome-Wide Investigation of SNPs and CNVs in Schizophrenia. <i>PLoS Genetics</i> , 2009, 5, e1000373.	3.5	383
234	Prediction of symptom remission in schizophrenia during inpatient treatment. <i>World Journal of Biological Psychiatry</i> , 2009, 10, 426-434.	2.6	18

#	ARTICLE	IF	CITATIONS
235	Disruption of the neurexin 1 gene is associated with schizophrenia. <i>Human Molecular Genetics</i> , 2009, 18, 988-996.	2.9	424
236	Use of Neuroanatomical Pattern Classification to Identify Subjects in At-Risk Mental States of Psychosis and Predict Disease Transition. <i>Archives of General Psychiatry</i> , 2009, 66, 700.	12.3	382
237	Increase of striatal dopamine transmission in first episode drug-naive schizophrenic patients as demonstrated by [123I]IBZM SPECT. <i>Psychiatry Research - Neuroimaging</i> , 2009, 173, 183-189.	1.8	23
238	Serotonin receptor HTR1A and HTR2C variants and personality traits in suicide attempters and controls. <i>Journal of Psychiatric Research</i> , 2009, 43, 519-525.	3.1	42
239	Inefficient neural activity in patients with schizophrenia and nonpsychotic relatives of schizophrenic patients: Evidence from a working memory task. <i>Journal of Psychiatric Research</i> , 2009, 43, 1185-1194.	3.1	43
240	Personality and attempted suicide. Analysis of anger, aggression and impulsivity. <i>Journal of Psychiatric Research</i> , 2009, 43, 1262-1271.	3.1	167
241	Attitude towards adherence in patients with schizophrenia at discharge. <i>Journal of Psychiatric Research</i> , 2009, 43, 1294-1301.	3.1	28
242	Does early improvement triggered by antidepressants predict response/remission? – Analysis of data from a naturalistic study on a large sample of inpatients with major depression. <i>Journal of Affective Disorders</i> , 2009, 115, 439-449.	4.1	150
243	Do the estrogen receptors 1 gene variants influence the temperament and character inventory scores in suicidal attempters and healthy subjects?. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2009, 150B, 434-438.	1.7	10
244	Regional networks underlying interhemispheric connectivity: An EEG and DTI study in healthy ageing and amnesic mild cognitive impairment. <i>Human Brain Mapping</i> , 2009, 30, 2098-2119.	3.6	85
245	The free choice whether or not to respond after stimulus presentation. <i>Human Brain Mapping</i> , 2009, 30, 2971-2985.	3.6	28
246	The problem of being a paradigm: the emergence of neural stem cells as example for “Kuhnian” revolution in biology or misconception of the scientific community?. <i>Poiesis &amp; Praxis</i> , 2009, 6, 3-11.	0.3	1
247	Creating a map of psychiatric patients based on psychopathological symptom profiles. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2009, 259, 164-171.	3.2	15
248	Internal capsule size associated with outcome in first-episode schizophrenia. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2009, 259, 278-283.	3.2	34
249	Is evidence sufficient for evidence-based medicine?. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2009, 259, 167-172.	3.2	9
250	Common variants conferring risk of schizophrenia. <i>Nature</i> , 2009, 460, 744-747.	27.8	1,572
251	Antidepressants and suicidality in younger adults – is bipolar illness the missing link?. <i>Acta Psychiatrica Scandinavica</i> , 2009, 119, 166-166.	4.5	10
252	Development of DSM-IV and ICD-11: Tendencies and potential of new classifications in psychiatry at the current state of knowledge. <i>Psychiatry and Clinical Neurosciences</i> , 2009, 63, 595-612.	1.8	40

#	ARTICLE	IF	CITATIONS
253	Is the significant superiority of escitalopram compared with other antidepressants clinically relevant?. <i>International Clinical Psychopharmacology</i> , 2009, 24, 111-118.	1.7	98
254	Defining and predicting functional outcome in schizophrenia and schizophrenia spectrum disorders. <i>Schizophrenia Research</i> , 2009, 113, 210-217.	2.0	97
255	Enfermedad cardiovascular y diabetes en personas con enfermedad mental grave. <i>Revista De Psiquiatría Y Salud Mental</i> , 2009, 2, 49-59.	1.8	16
256	Cardiovascular disease and diabetes in people with severe mental illness. <i>Revista De Psiquiatría Y Salud Mental (English Edition)</i> , 2009, 2, 49-59.	0.3	10
257	Antidepressants: Controversies about their efficacy in depression, their effect on suicidality and their place in a complex psychiatric treatment approach. <i>World Journal of Biological Psychiatry</i> , 2009, 10, 180-195.	2.6	21
258	The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2009 on the Treatment of Acute Mania. <i>World Journal of Biological Psychiatry</i> , 2009, 10, 85-116.	2.6	302
259	Standardised rating scales in Psychiatry: Methodological basis, their possibilities and limitations and descriptions of important rating scales. <i>World Journal of Biological Psychiatry</i> , 2009, 10, 6-26.	2.6	80
260	Comparison of racemic ketamine and <i>S</i> -ketamine in treatment-resistant major depression: Report of two cases. <i>World Journal of Biological Psychiatry</i> , 2009, 10, 241-244.	2.6	85
261	Decreased Activation Along the Dorsal Visual Pathway After a 3-Month Treatment With Galantamine in Mild Alzheimer Disease. <i>Journal of Clinical Psychopharmacology</i> , 2009, 29, 147-156.	1.4	35
262	Influence of 5-HT <sub>3</sub> receptor subunit genes HTR3A, HTR3B, HTR3C, HTR3D and HTR3E on treatment response to antipsychotics in schizophrenia. <i>Pharmacogenetics and Genomics</i> , 2009, 19, 843-851.	1.5	30
263	White Matter Microstructure in Relation to Education in Aging and Alzheimer's Disease <sup>1</sup> . <i>Journal of Alzheimer's Disease</i> , 2009, 17, 571-583.	2.6	84
264	Lithium Trial in Alzheimer's Disease. <i>Journal of Clinical Psychiatry</i> , 2009, 70, 922-931.	2.2	252
265	Side effect burden of antipsychotic medication. <i>Medical Psychiatry</i> , 2009, , 231-259.	0.2	1
266	SNAP-25 genotype influences NAA/Cho in left hippocampus. <i>Journal of Neural Transmission</i> , 2008, 115, 1513-1518.	2.8	11
267	White matter alterations in schizophrenic patients with pronounced negative symptomatology and with positive family history for schizophrenia. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2008, 258, 278-284.	3.2	13
268	Associations of SNAP-25 polymorphisms with cognitive dysfunctions in Caucasian patients with schizophrenia during a brief trial of treatment with atypical antipsychotics. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2008, 258, 335-344.	3.2	32
269	Do effectiveness (‘‘real world’’) studies on antipsychotics tell us the real truth?. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2008, 258, 257-270.	3.2	33
270	Systematic of psychiatric disorders between categorical and dimensional approaches. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2008, 258, 48-73.	3.2	95



#	ARTICLE	IF	CITATIONS
271	Do SSRIs or antidepressants in general increase suicidality?. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2008, 258, 3-23.	3.2	83
272	The forthcoming revision of the diagnostic and classificatory system: perspectives based on the European psychiatric tradition. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2008, 258, 7-17.	3.2	21
273	Neuropsychological impairments predict the clinical course in schizophrenia. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2008, 258, 28-34.	3.2	54
274	NOS1 and 11 gene variants are differentially associated with facets of suicidal behavior and aggression-related traits. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2008, 147B, 42-48.	1.7	50
275	Dopa decarboxylase and tyrosine hydroxylase gene variants in suicidal behavior. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2008, 147B, 308-315.	1.7	16
276	Reduced hippocampal volumes associated with the long variant of the triallelic serotonin transporter polymorphism in major depression. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2008, 147B, 1003-1007.	1.7	74
277	Large recurrent microdeletions associated with schizophrenia. <i>Nature</i> , 2008, 455, 232-236.	27.8	1,619
278	Identification of loci associated with schizophrenia by genome-wide association and follow-up. <i>Nature Genetics</i> , 2008, 40, 1053-1055.	21.4	977
279	Cognitive functioning in euthymic bipolar I and bipolar II patients. <i>Bipolar Disorders</i> , 2008, 10, 877-887.	1.9	95
280	Atypical symptoms in hospitalised patients with major depressive episode: frequency, clinical characteristics, and internal validity. <i>Journal of Affective Disorders</i> , 2008, 108, 271-278.	4.1	32
281	Temperament and character of suicide attempters. <i>Journal of Psychiatric Research</i> , 2008, 42, 938-945.	3.1	63
282	SNAP-25 gene polymorphisms and weight gain in schizophrenic patients. <i>Journal of Psychiatric Research</i> , 2008, 42, 963-970.	3.1	38
283	Anterior cingulate cortex does not differ between patients with major depression and healthy controls, but relatively large anterior cingulate cortex predicts a good clinical course. <i>Psychiatry Research - Neuroimaging</i> , 2008, 163, 76-83.	1.8	49
284	Functional abnormalities of the visual processing system in subjects with mild cognitive impairment: An fMRI study. <i>Psychiatry Research - Neuroimaging</i> , 2008, 163, 248-259.	1.8	52
285	World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders – First Revision. <i>World Journal of Biological Psychiatry</i> , 2008, 9, 248-312.	2.6	661
286	Evaluation of the German WPA –Program against stigma and discrimination because of schizophrenia – “Open the Doors” Results from representative telephone surveys before and after three years of antistigma interventions. <i>Schizophrenia Research</i> , 2008, 98, 184-193.	2.0	64
287	Depression during an acute episode of schizophrenia or schizophreniform disorder and its impact on treatment response. <i>Psychiatry Research</i> , 2008, 158, 297-305.	3.3	24
288	Estrogen receptor gene 1 variants are not associated with suicidal behavior. <i>Psychiatry Research</i> , 2008, 160, 1-7.	3.3	14

#	ARTICLE	IF	CITATIONS
289	Influence of trait anxiety on inhibitory control in alcohol-dependent patients: Simultaneous acquisition of ERPs and BOLD responses. <i>Journal of Psychiatric Research</i> , 2008, 42, 734-745.	3.1	55
290	Structural correlates of psychopathological symptom dimensions in schizophrenia: A voxel-based morphometric study. <i>NeuroImage</i> , 2008, 39, 1600-1612.	4.2	166
291	Single-trial coupling of EEG and fMRI reveals the involvement of early anterior cingulate cortex activation in effortful decision making. <i>NeuroImage</i> , 2008, 42, 158-168.	4.2	133
292	A meta-analysis of clinical trials comparing reboxetine, a norepinephrine reuptake inhibitor, with selective serotonin reuptake inhibitors for the treatment of major depressive disorder. <i>European Neuropsychopharmacology</i> , 2008, 18, 122-127.	0.7	64
293	World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Substance Use and Related Disorders, Part 1: Alcoholism. <i>World Journal of Biological Psychiatry</i> , 2008, 9, 6-23.	2.6	67
294	Outcomes in major depressive disorder: The evolving concept of remission and its implications for treatment. <i>World Journal of Biological Psychiatry</i> , 2008, 9, 102-114.	2.6	95
295	How to grade categories of evidence. <i>World Journal of Biological Psychiatry</i> , 2008, 9, 242-247.	2.6	22
296	Duloxetine in the treatment of major psychiatric and neuropathic disorders. <i>Expert Review of Neurotherapeutics</i> , 2008, 8, 527-536.	2.8	184
297	Depression-Related Variation in Brain Morphology Over 3 Years. <i>Archives of General Psychiatry</i> , 2008, 65, 1156.	12.3	329
298	Gene expression profiling of post-mortem orbitofrontal cortex in violent suicide victims. <i>International Journal of Neuropsychopharmacology</i> , 2008, 11, 217-28.	2.1	66
299	The assessment of cognitive impairment would be a relevant addition to the criteria for diagnosing schizophrenia. <i>World Psychiatry</i> , 2008, 7, 35-36.	10.4	4
300	EDITORIAL. <i>World Journal of Biological Psychiatry</i> , 2008, 9, 82-85.	2.6	13
301	Association of functional polymorphisms in NOS1 and NOS3 with loudness dependence of auditory evoked potentials. <i>International Journal of Neuropsychopharmacology</i> , 2008, 11, 477-83.	2.1	20
302	Short-term treatment with risperidone or haloperidol in first-episode schizophrenia: 8-week results of a randomized controlled trial within the German Research Network on Schizophrenia. <i>International Journal of Neuropsychopharmacology</i> , 2008, 11, 985-97.	2.1	55
303	Evaluation of the feasibility of switching from immediate release quetiapine to extended release quetiapine fumarate in stable outpatients with schizophrenia. <i>International Clinical Psychopharmacology</i> , 2008, 23, 95-105.	1.7	18
304	Electroconvulsive therapy and its different indications. <i>Dialogues in Clinical Neuroscience</i> , 2008, 10, 105-117.	3.7	111
305	Effects of different antidepressant treatments on the core of depression. <i>Dialogues in Clinical Neuroscience</i> , 2008, 10, 309-320.	3.7	5
306	Drug Treatment of Depressive Symptoms in Schizophrenia. <i>Clinical Schizophrenia and Related Psychoses</i> , 2008, 1, 328-340.	1.4	15

#	ARTICLE	IF	CITATIONS
307	The Impact of Homocysteine Levels on Cognition in Euthymic Bipolar Patients. <i>Journal of Clinical Psychiatry</i> , 2008, 69, 899-906.	2.2	41
308	The Impact of Reboxetine and Mirtazapine on Driving Simulator Performance and Psychomotor Function in Depressed Patients. <i>Journal of Clinical Psychiatry</i> , 2008, 69, 1880-1886.	2.2	44
309	Effect of hippocampal and amygdala volumes on clinical outcomes in major depression: a 3-year prospective magnetic resonance imaging study. <i>Journal of Psychiatry and Neuroscience</i> , 2008, 33, 423-30.	2.4	211
310	Influence of Anxiety on Electrophysiological Correlates of Response Inhibition Capacities in Alcoholism. <i>Clinical EEG and Neuroscience</i> , 2007, 38, 89-95.	1.7	14
311	Do effectiveness studies tell us the real truth?. <i>World Journal of Biological Psychiatry</i> , 2007, 8, 138-140.	2.6	3
312	Fiber Connections between the Cerebral Cortex and the Corpus Callosum in Alzheimer's Disease: A Diffusion Tensor Imaging and Voxel-Based Morphometry Study. <i>Cerebral Cortex</i> , 2007, 17, 2276-2282.	2.9	74
313	Molecular Genetic Findings in Suicidal Behavior: What is Beyond the Serotonergic System?. <i>Archives of Suicide Research</i> , 2007, 11, 17-40.	2.3	66
314	Acute effects of treatment for prodromal symptoms for people putatively in a late initial prodromal state of psychosis. <i>British Journal of Psychiatry</i> , 2007, 191, s88-s95.	2.8	122
315	Association of the Brain-Derived Neurotrophic Factor Val66Met Polymorphism With Reduced Hippocampal Volumes in Major Depression. <i>Archives of General Psychiatry</i> , 2007, 64, 410.	12.3	357
316	Rostral Anterior Cingulate Cortex Activity in the Theta Band Predicts Response to Antidepressive Medication. <i>Clinical EEG and Neuroscience</i> , 2007, 38, 78-81.	1.7	84
317	Evidence of agomelatine's antidepressant efficacy: the key points. <i>International Clinical Psychopharmacology</i> , 2007, 22, S15-S19.	1.7	25
318	A double blind, randomized, placebo-controlled trial of quetiapine as an add-on therapy to lithium or divalproex for the treatment of bipolar mania. <i>International Clinical Psychopharmacology</i> , 2007, 22, 212-220.	1.7	64
319	Which antidepressants have demonstrated superior efficacy? A review of the evidence. <i>International Clinical Psychopharmacology</i> , 2007, 22, 323-329.	1.7	137
320	Morphological substrate of face matching in healthy ageing and mild cognitive impairment: a combined MRI-fMRI study. <i>Brain</i> , 2007, 130, 1745-1758.	7.6	47
321	5-HT2A SNPs and the Temperament and Character Inventory. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2007, 31, 1275-1281.	4.8	32
322	ABCG1 gene variants in suicidal behavior and aggression-related traits. <i>European Neuropsychopharmacology</i> , 2007, 17, 410-416.	0.7	24
323	Clinical evaluation of negative symptoms in schizophrenia. <i>European Psychiatry</i> , 2007, 22, 380-386.	0.2	78
324	Multivariate network analysis of fiber tract integrity in Alzheimer's disease. <i>NeuroImage</i> , 2007, 34, 985-995.	4.2	162

#	ARTICLE	IF	CITATIONS
325	Multivariate deformation-based analysis of brain atrophy to predict Alzheimer's disease in mild cognitive impairment. <i>NeuroImage</i> , 2007, 38, 13-24.	4.2	185
326	World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders in Primary Care. <i>World Journal of Biological Psychiatry</i> , 2007, 8, 67-104.	2.6	335
327	Alterations of hippocampal and prefrontal GABAergic interneurons in an animal model of psychosis induced by NMDA receptor antagonism. <i>Schizophrenia Research</i> , 2007, 97, 254-263.	2.0	106
328	In-vivo topography of structural alterations of the anterior cingulate in patients with schizophrenia: New findings and comparison with the literature. <i>Schizophrenia Research</i> , 2007, 96, 34-45.	2.0	21
329	Long-Acting Injectable Risperidone for the Treatment of Schizophrenia. <i>Drugs</i> , 2007, 67, 1541-1566.	10.9	47
330	World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Personality Disorders. <i>World Journal of Biological Psychiatry</i> , 2007, 8, 212-244.	2.6	136
331	<i>HTR2C</i> and <i>HTR1A</i> gene variants in German and Italian suicide attempters and completers. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2007, 144B, 291-299.	1.7	70
332	Tachykinin receptor 1 variants associated with aggression in suicidal behavior. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2007, 144B, 757-761.	1.7	17
333	Depressive, anxiety, and somatoform disorders in primary care: prevalence and recognition. <i>Depression and Anxiety</i> , 2007, 24, 185-195.	4.1	138
334	Randomized controlled multicentre trial of cognitive behaviour therapy in the early initial prodromal state: effects on social adjustment post treatment. <i>Microbial Biotechnology</i> , 2007, 1, 71-78.	1.7	54
335	Prediction of treatment response in major depression: Integration of concepts. <i>Journal of Affective Disorders</i> , 2007, 98, 215-225.	4.1	142
336	Hippocampal volume reduction and history of aggressive behaviour in patients with borderline personality disorder. <i>Psychiatry Research - Neuroimaging</i> , 2007, 154, 157-170.	1.8	82
337	Acute prefrontal rTMS increases striatal dopamine to a similar degree as d-amphetamine. <i>Psychiatry Research - Neuroimaging</i> , 2007, 156, 251-255.	1.8	103
338	Auditory cortex and anterior cingulate cortex sources of the early evoked gamma-band response: Relationship to task difficulty and mental effort. <i>Neuropsychologia</i> , 2007, 45, 2294-2306.	1.6	88
339	Analysis of tryptophan hydroxylase I and II mRNA expression in the human brain: A post-mortem study. <i>Journal of Psychiatric Research</i> , 2007, 41, 168-173.	3.1	157
340	Decreased T cellular immune response in schizophrenic patients. <i>Journal of Psychiatric Research</i> , 2007, 41, 3-7.	3.1	70
341	Psychopathological characteristics and treatment response of first episode compared with multiple episode schizophrenic disorders. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2007, 257, 47-53.	3.2	58
342	Effects of risperidone and quetiapine on cognition in patients with schizophrenia and predominantly negative symptoms. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2007, 257, 360-370.	3.2	47

#	ARTICLE	IF	CITATIONS
343	Efficacy of olanzapine versus quetiapine on cognitive dysfunctions in patients with an acute episode of schizophrenia. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2007, 257, 402-412.	3.2	40
344	[123I] ADAM brainstem binding correlates with the loudness dependence of auditory evoked potentials. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2007, 258, 40-47.	3.2	11
345	Quetiapine in the treatment of schizophrenia and related disorders. <i>Neuropsychiatric Disease and Treatment</i> , 2007, 3, 219-235.	2.2	56
346	Maintenance Treatment With Risperidone or Low-Dose Haloperidol in First-Episode Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2007, 68, 1763-1774.	2.2	76
347	Evaluación clínica de los síntomas negativos de la esquizofrenia. <i>European Psychiatry (Ed Española)</i> , 2007, 14, 375-382.	0.0	0
348	Schizophrenie und schizophreniforme Störungen. , 2007, , 1507-1518.		0
349	[I-123] ADAM and SPECT in patients with borderline personality disorder and healthy control subjects. <i>Journal of Psychiatry and Neuroscience</i> , 2007, 32, 234-40.	2.4	41
350	Duloxetine: a new selective and dual-acting antidepressant. <i>Expert Opinion on Pharmacotherapy</i> , 2006, 7, 421-427.	1.8	20
351	GABA <sub>A</sub> receptors as targets for novel anxiolytic drugs. <i>World Journal of Biological Psychiatry</i> , 2006, 7, 231-237.	2.6	26
352	Drug treatment of depression in the 2000s: an overview of achievements in the last 10 years and future possibilities. <i>World Journal of Biological Psychiatry</i> , 2006, 7, 198-222.	2.6	42
353	Ethical aspects of publishing. <i>World Journal of Biological Psychiatry</i> , 2006, 7, 66-69.	2.6	6
354	The influence of concomitant antidepressant medication on safety, tolerability and clinical effectiveness of electroconvulsive therapy. <i>World Journal of Biological Psychiatry</i> , 2006, 7, 82-90.	2.6	41
355	The influence of concomitant neuroleptic medication on safety, tolerability and clinical effectiveness of electroconvulsive therapy. <i>World Journal of Biological Psychiatry</i> , 2006, 7, 162-170.	2.6	46
356	A Pharmacological Model for Psychosis Based on N-methyl-D-aspartate Receptor Hypofunction: Molecular, Cellular, Functional and Behavioral Abnormalities. <i>Biological Psychiatry</i> , 2006, 59, 721-729.	1.3	219
357	Amygdala Volume and Depressive Symptoms in Patients With Borderline Personality Disorder. <i>Biological Psychiatry</i> , 2006, 60, 302-310.	1.3	96
358	Factor structure and external validity of the PANSS revisited. <i>Schizophrenia Research</i> , 2006, 82, 213-223.	2.0	124
359	Long-acting risperidone: Focus on safety. <i>Clinical Therapeutics</i> , 2006, 28, 633-651.	2.5	24
360	Treatment of depression with atypical features: A meta-analytic approach. <i>Psychiatry Research</i> , 2006, 141, 89-101.	3.3	125

#	ARTICLE	IF	CITATIONS
361	Dissociation between CSF total tau and tau protein phosphorylated at threonine 231 in Creutzfeldt-Jakob disease. <i>Neurobiology of Aging</i> , 2006, 27, 10-15.	3.1	69
362	Diretrizes da Federação Mundial das Sociedades de Psiquiatria Biológica para o tratamento biológico da esquizofrenia. Parte 1: tratamento agudo. <i>Revista De Psiquiatria Clínica</i> , 2006, 33, 7-64.	0.6	9
363	Do recent efficacy data on the drug treatment of acute bipolar depression support the position that drugs other than antidepressants are the treatment of choice?. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2006, 256, 1-16.	3.2	61
364	Evidence for beneficial effects of antidepressants on suicidality in depressive patients. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2006, 256, 329-343.	3.2	51
365	Is there evidence for negative effects of antidepressants on suicidality in depressive patients?. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2006, 256, 476-496.	3.2	57
366	Comprehensive dissection of the medial temporal lobe in AD: measurement of hippocampus, amygdala, entorhinal, perirhinal and parahippocampal cortices using MRI. <i>Journal of Neurology</i> , 2006, 253, 794-800.	3.6	106
367	Effects of donepezil on cortical metabolic response to activation during 18FDG-PET in Alzheimer's disease: a double-blind cross-over trial. <i>Psychopharmacology</i> , 2006, 187, 86-94.	3.1	62
368	Distinct seasonality of depressive episodes differentiates unipolar depressive patients with and without depressive mixed states. <i>Journal of Affective Disorders</i> , 2006, 90, 1-5.	4.1	16
369	Anger- and aggression-related traits are associated with polymorphisms in the 5-HT-2A gene. <i>Journal of Affective Disorders</i> , 2006, 96, 75-81.	4.1	98
370	Striatal dopamine release after prefrontal repetitive transcranial magnetic stimulation in major depression: Preliminary results of a dynamic [123I] IBZM SPECT study. <i>Journal of Psychiatric Research</i> , 2006, 40, 307-314.	3.1	161
371	World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 2: Long-term treatment of schizophrenia. <i>World Journal of Biological Psychiatry</i> , 2006, 7, 5-40.	2.6	194
372	A Ser9Gly Polymorphism in the Dopamine D3 Receptor Gene (DRD3) and Event-Related P300 Potentials. <i>Neuropsychopharmacology</i> , 2006, 31, 1335-1344.	5.4	58
373	Recent Progress in Pharmacological and Non-Pharmacological Treatment Options of Major Depression. <i>Current Pharmaceutical Design</i> , 2006, 12, 503-515.	1.9	49
374	The German Research Network on Schizophrenia-impact on the management of schizophrenia. <i>Dialogues in Clinical Neuroscience</i> , 2006, 8, 115-121.	3.7	14
375	Antidepressants and Driving Ability. <i>Journal of Clinical Psychiatry</i> , 2006, 67, 1776-1781.	2.2	73
376	Das Publizieren in der Psychiatrie. , 2006, , 199-221.		1
377	Reduced hippocampal volume correlates with executive dysfunctioning in major depression. <i>Journal of Psychiatry and Neuroscience</i> , 2006, 31, 316-23.	2.4	178
378	Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies. <i>International Clinical Psychopharmacology</i> , 2005, 20, 121-130.	1.7	105

#	ARTICLE	IF	CITATIONS
379	Effects of haloperidol and risperidone on psychomotor performance relevant to driving ability in schizophrenic patients compared to healthy controls. <i>Journal of Psychiatric Research</i> , 2005, 39, 101-108.	3.1	45
380	Pattern of interleukin-6 receptor complex immunoreactivity between cortical regions of rapid autopsy normal and Alzheimer's disease brain. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2005, 255, 269-278.	3.2	59
381	The influence of 4-week treatment with sertraline on the combined T3/TRH test in depressed patients. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2005, 255, 334-340.	3.2	4
382	Antidepressive effects of traditional and second generation antipsychotics: a review of the clinical data. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2005, 255, 83-93.	3.2	53
383	Antipsychotic and antidepressive effects of second generation antipsychotics. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2005, 255, 190-201.	3.2	74
384	Metaanalyses' highest level of empirical evidence?. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2005, 255, 369-370.	3.2	19
385	Quetiapine has equivalent efficacy and superior tolerability to risperidone in the treatment of schizophrenia with predominantly negative symptoms. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2005, 255, 432-437.	3.2	49
386	Are the new antipsychotics no better than the classical neuroleptics?. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2005, 255, 371-372.	3.2	16
387	Driving ability in schizophrenic patients: effects of neuroleptics. <i>International Journal of Psychiatry in Clinical Practice</i> , 2005, 9, 168-174.	2.4	7
388	Risperidone: a review. <i>Expert Opinion on Pharmacotherapy</i> , 2005, 6, 803-818.	1.8	56
389	Problems associated with the classification and diagnosis of psychiatric disorders. <i>World Journal of Biological Psychiatry</i> , 2005, 6, 45-56.	2.6	25
390	Saccadic Eye Velocity after Selective GABAergic Treatment with Tiagabine in Healthy Volunteers. <i>Neuropsychobiology</i> , 2005, 52, 147-150.	1.9	5
391	Correlation of Cerebrospinal Fluid Levels of Tau Protein Phosphorylated at Threonine 231 With Rates of Hippocampal Atrophy in Alzheimer Disease. <i>Archives of Neurology</i> , 2005, 62, 770.	4.5	158
392	Measurement of basal forebrain atrophy in Alzheimer's disease using MRI. <i>Brain</i> , 2005, 128, 2626-2644.	7.6	213
393	ICAM G241A Polymorphism and Soluble ICAM-1 Serum Levels: Evidence for an Active Immune Process in Schizophrenia. <i>NeuroImmunoModulation</i> , 2005, 12, 54-59.	1.8	31
394	Sound level dependence of the primary auditory cortex: Simultaneous measurement with 61-channel EEG and fMRI. <i>NeuroImage</i> , 2005, 28, 49-58.	4.2	162
395	Are placebo-controlled studies required in order to prove efficacy of antidepressants?. <i>World Journal of Biological Psychiatry</i> , 2005, 6, 130-131.	2.6	5
396	World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 1: Acute treatment of schizophrenia. <i>World Journal of Biological Psychiatry</i> , 2005, 6, 132-191.	2.6	242

#	ARTICLE	IF	CITATIONS
397	Fifteen-year follow-up of Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition depressive disorders: the prognostic significance of psychotic features. <i>Comprehensive Psychiatry</i> , 2005, 46, 322-327.	3.1	16
398	Decreased serum amyloid $\beta$ 1-42 autoantibody levels in Alzheimer's disease, determined by a newly developed immuno-precipitation assay with radiolabeled amyloid $\beta$ 1-42 peptide. <i>Biological Psychiatry</i> , 2005, 57, 813-816.	1.3	70
399	Occurrence and treatment of depressive comorbidity/cosyndromality in schizophrenic psychoses: conceptual and treatment issues. <i>World Journal of Biological Psychiatry</i> , 2005, 6, 247-263.	2.6	54
400	Schizophrene und schizophreniforme Störungen. , 2005, , 1342-1351.		0
401	Measurement of Phosphorylated Tau Epitopes in the Differential Diagnosis of Alzheimer Disease. <i>Archives of General Psychiatry</i> , 2004, 61, 95.	12.3	390
402	Kinematical Analysis of Motor Function in Schizophrenic Patients: a Possibility to Separate Negative Symptoms from Extrapiramidal Dysfunction Induced by Neuroleptics?. <i>Pharmacopsychiatry</i> , 2004, 37, 110-118.	3.3	14
403	Classification of Functional Psychoses and Its Implication for Prognosis: Comparison between ICD-10 and DSM-IV. <i>Psychopathology</i> , 2004, 37, 110-117.	1.5	30
404	Novel Antipsychotics in the Long-term Treatment of Schizophrenia. <i>World Journal of Biological Psychiatry</i> , 2004, 5, 9-19.	2.6	23
405	Age-related cortical grey matter reductions in nondemented Down's syndrome adults determined by MRI with voxel-based morphometry. <i>Brain</i> , 2004, 127, 811-824.	7.6	135
406	Access to The World Journal of Biological Psychiatry. <i>World Journal of Biological Psychiatry</i> , 2004, 5, 118-119.	2.6	2
407	SSRIs: Are the accusations justified. <i>World Journal of Biological Psychiatry</i> , 2004, 5, 174-175.	2.6	4
408	Serotonin and Dopamine Transporter Availabilities Correlate with the Loudness Dependence of Auditory Evoked Potentials in Patients with Obsessive-Compulsive Disorder. <i>Neuropsychopharmacology</i> , 2004, 29, 1910-1917.	5.4	53
409	Mixed depressive features predict maniform switch during treatment of depression in bipolar I disorder. <i>Journal of Affective Disorders</i> , 2004, 78, 149-152.	4.1	79
410	Depression with atypical features in a sample of primary care outpatients: prevalence, specific characteristics and consequences. <i>Journal of Affective Disorders</i> , 2004, 83, 237-242.	4.1	29
411	Use of brief depression screening tools in primary care: consideration of heterogeneity in performance in different patient groups. <i>General Hospital Psychiatry</i> , 2004, 26, 190-198.	2.4	116
412	Screening for depression in primary care: Will one or two items suffice?. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2004, 254, 215-23.	3.2	63
413	COX-2 inhibition as a treatment approach in schizophrenia: Immunological considerations and clinical effects of celecoxib add-on therapy. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2004, 254, 14-22.	3.2	126
414	Should combined pharmaco- and psychotherapy be offered to depressed patients?. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2004, 254, 99-107.	3.2	35



#	ARTICLE	IF	CITATIONS
415	Non-neuroleptic approaches to treating negative symptoms in schizophrenia. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2004, 254, 108-116.	3.2	38
416	Early detection and secondary prevention of psychosis: facts and visions*. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2004, 254, 117-128.	3.2	183
417	Pharmacological long-term treatment strategies in first episode schizophrenia. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2004, 254, 129-140.	3.2	52
418	The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders, Part III: Maintenance Treatment. <i>World Journal of Biological Psychiatry</i> , 2004, 5, 120-135.	2.6	124
419	Psychopathology of early-onset versus late-onset schizophrenia revisited: an observation of 473 neuroleptic-naive patients before and after first-admission treatments. <i>Schizophrenia Research</i> , 2004, 67, 175-183.	2.0	59
420	Single nucleotide polymorphism and haplotype analysis of a novel tryptophan hydroxylase Isoform (TPH2) gene in suicide victims. <i>Biological Psychiatry</i> , 2004, 56, 581-586.	1.3	193
421	Cincinnati criteria for mixed mania and suicidality in patients with acute mania. <i>Comprehensive Psychiatry</i> , 2004, 45, 62-69.	3.1	23
422	Integration of fMRI and simultaneous EEG: towards a comprehensive understanding of localization and time-course of brain activity in target detection. <i>NeuroImage</i> , 2004, 22, 83-94.	4.2	555
423	The Impact of Antipsychotics on Psychomotor Performance With Regards to Car Driving Skills. <i>Journal of Clinical Psychopharmacology</i> , 2004, 24, 155-160.	1.4	58
424	Reduced Hippocampal Volumes Associated With the Long Variant of the Serotonin Transporter Polymorphism in Major Depression. <i>Archives of General Psychiatry</i> , 2004, 61, 177.	12.3	164
425	Hippocampal and Amygdala Changes in Patients With Major Depressive Disorder and Healthy Controls During a 1-Year Follow-Up. <i>Journal of Clinical Psychiatry</i> , 2004, 65, 492-499.	2.2	188
426	Schizoaffektive Psychosen und sonstige wahnhaftige Störungen nicht organischer Genese. , 2004, , 160-188.		0
427	Schizophrene Psychosen. , 2004, , 109-160.		0
428	Extrapyramidal-motorische Störungen (EPS): Ihre Bedeutung zu Zeiten der klassischen Neuroleptika im Vergleich zur modernen Antipsychotika-Therapie. , 2004, , 19-60.		0
429	Attenuation of hypothalamic-pituitary-adrenocortical hyperactivity in depressed patients by mirtazapine. <i>Psychopharmacology</i> , 2003, 166, 271-275.	3.1	54
430	Placebo-controlled studies in depression: necessary, ethical and feasible. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2003, 253, 22-28.	3.2	59
431	Polymorphisms of the gene encoding the inflammatory cytokine interleukin-6 determine the magnitude of the increase in soluble interleukin-6 receptor levels in Alzheimer's disease. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2003, 253, 44-48.	3.2	28
432	Is lithium still the gold standard in the treatment of bipolar disorders?. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2003, 253, 113-114.	3.2	2

#	ARTICLE	IF	CITATIONS
433	German research network on schizophrenia. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2003, 253, 321-329.	3.2	67
434	Effects of antidepressant pharmacotherapy after repetitive transcranial magnetic stimulation in major depression: an open follow-up study. <i>Journal of Psychiatric Research</i> , 2003, 37, 145-153.	3.1	24
435	Effects of tiagabine on cholecystokinin-tetrapeptide (CCK-4)-induced anxiety in healthy volunteers. <i>Depression and Anxiety</i> , 2003, 18, 140-143.	4.1	38
436	Lack of association between serotonin 5-HT1B receptor gene polymorphism and suicidal behavior. , 2003, 116B, 69-71.		38
437	Psychopharmacotherapy of somatoform disorders: effects of opipramol on symptoms of somatization, anxiety, and depression. <i>Acta Neuropsychiatrica</i> , 2003, 15, 217-226.	2.1	14
438	Repetitive Transcranial Magnetic Stimulation. <i>CNS Drugs</i> , 2003, 17, 383-403.	5.9	50
439	Larger amygdala volumes in first depressive episode as compared to recurrent major depression and healthy control subjects. <i>Biological Psychiatry</i> , 2003, 53, 338-344.	1.3	238
440	Substance P serum levels are increased in major depression: preliminary results. <i>Biological Psychiatry</i> , 2003, 53, 538-542.	1.3	113
441	Genetic variations in tryptophan hydroxylase in suicidal behavior. <i>Biological Psychiatry</i> , 2003, 54, 465-473.	1.3	137
442	A functional single nucleotide polymorphism (V158M) in the COMT gene is associated with aggressive personality traits. <i>Biological Psychiatry</i> , 2003, 54, 34-39.	1.3	162
443	The impact of the duration of untreated psychosis prior to first psychiatric admission on the 15-year outcome in schizophrenia. <i>Schizophrenia Research</i> , 2003, 62, 37-44.	2.0	127
444	Serotonergic dysfunction in schizophrenia assessed by the loudness dependence measure of primary auditory cortex evoked activity. <i>Schizophrenia Research</i> , 2003, 64, 115-124.	2.0	82
445	Amisulpride: limbic specificity and the mechanism of antipsychotic atypicality. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2003, 27, 1101-1111.	4.8	78
446	Elevated brain serotonin transporter availability in patients with obsessive-compulsive disorder. <i>Biological Psychiatry</i> , 2003, 54, 1406-1413.	1.3	108
447	Reliability and validity of Quality of Life assessed by the Short-Form 36 and the Modular System for Quality of Life in patients with schizophrenia and patients with depression. <i>Psychiatry Research</i> , 2003, 119, 63-79.	3.3	87
448	Management of the Negative Symptoms of Schizophrenia. <i>CNS Drugs</i> , 2003, 17, 793-823.	5.9	111
449	Response to letter to the editor from Andrade et al. (2003) ECT in the management of major depression: Implications of recent research, <i>World J Biol Psychiatry</i> 4: 139-140. <i>World Journal of Biological Psychiatry</i> , 2003, 4, 140-141.	2.6	0
450	Effects of Haloperidol and Atypical Neuroleptics on Psychomotor Performance and Driving Ability in Schizophrenic Patients. <i>Neuropsychobiology</i> , 2003, 47, 212-218.	1.9	33

#	ARTICLE	IF	CITATIONS
451	Identifying depression in primary care: a comparison of different methods in a prospective cohort study. <i>BMJ: British Medical Journal</i> , 2003, 326, 200-201.	2.3	243
452	Differentiation of Geriatric Major Depression From Alzheimer's Disease With CSF Tau Protein Phosphorylated at Threonine 231. <i>American Journal of Psychiatry</i> , 2003, 160, 376-379.	7.2	83
453	The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders, Part II: Treatment of Mania. <i>World Journal of Biological Psychiatry</i> , 2003, 4, 5-13.	2.6	148
454	Relation of Corpus Callosum and Hippocampal Size to Age in Nondemented Adults With Down's Syndrome. <i>American Journal of Psychiatry</i> , 2003, 160, 1870-1878.	7.2	96
455	Improving the chance of recovery from the short- and long-term consequences of depression. <i>International Clinical Psychopharmacology</i> , 2003, 18, 219-225.	1.7	15
456	The impact of the duration of untreated psychosis on short- and long-term outcome in schizophrenia. <i>Current Opinion in Psychiatry</i> , 2003, 16, S39-S43.	6.3	18
457	Chapter 42 Prefrontal cortex stimulation as antidepressant treatment: mode of action and clinical effectiveness of rTMS. <i>Supplements To Clinical Neurophysiology</i> , 2003, 56, 406-432.	2.1	11
458	On the Descriptive Validity of ICD-10 Schizophrenia: Empirical Analyses in the Spectrum of Non-Affective Functional Psychoses. <i>Psychopathology</i> , 2003, 36, 152-159.	1.5	36
459	Negative Symptoms in Depressed and Schizophrenic Patients. <i>Journal of Clinical Psychiatry</i> , 2003, 64, 954-958.	2.2	39
460	Psychiatrische Erkrankungen. , 2003, , 1265-1384.		0
461	Bipolar disorder and schizophrenia: distinct illnesses or a continuum?. <i>Journal of Clinical Psychiatry</i> , 2003, 64 Suppl 6, 23-7; discussion 28.	2.2	28
462	Differential Diagnosis of Alzheimer Disease With Cerebrospinal Fluid Levels of Tau Protein Phosphorylated at Threonine 231. <i>Archives of Neurology</i> , 2002, 59, 1267.	4.5	256
463	World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 2: Maintenance Treatment of Major Depressive Disorder and Treatment of Chronic Depressive Disorders and Subthreshold Depressions. <i>World Journal of Biological Psychiatry</i> , 2002, 3, 69-86.	2.6	131
464	Syndromes and Phenomenological Subtypes Underlying Acute Mania: A Factor Analytic Study of 576 Manic Patients. <i>American Journal of Psychiatry</i> , 2002, 159, 968-974.	7.2	118
465	World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Acute and Continuation Treatment of Major Depressive Disorder. <i>World Journal of Biological Psychiatry</i> , 2002, 3, 5-43.	2.6	311
466	Beneficial Antipsychotic Effects of Celecoxib Add-On Therapy Compared to Risperidone Alone in Schizophrenia. <i>American Journal of Psychiatry</i> , 2002, 159, 1029-1034.	7.2	366
467	Hippocampal Changes in Patients With a First Episode of Major Depression. <i>American Journal of Psychiatry</i> , 2002, 159, 1112-1118.	7.2	464
468	Progression of Corpus Callosum Atrophy in Alzheimer Disease. <i>Archives of Neurology</i> , 2002, 59, 243.	4.5	167

#	ARTICLE	IF	CITATIONS
469	Age transformation of combined hippocampus and amygdala volume improves diagnostic accuracy in Alzheimer's disease. <i>Journal of the Neurological Sciences</i> , 2002, 194, 15-19.	0.6	47
470	Enlargement of the amygdala in patients with a first episode of major depression. <i>Biological Psychiatry</i> , 2002, 51, 708-714.	1.3	285
471	The Kraepelinian dichotomy: preliminary results of a 15-year follow-up study on functional psychoses: focus on negative symptoms. <i>Schizophrenia Research</i> , 2002, 56, 87-94.	2.0	70
472	World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Posttraumatic Stress Disorders. <i>World Journal of Biological Psychiatry</i> , 2002, 3, 171-199.	2.6	155
473	World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Bipolar Disorders, Part I: Treatment of Bipolar Depression. <i>World Journal of Biological Psychiatry</i> , 2002, 3, 115-124.	2.6	161
474	P300 subcomponents in obsessive-compulsive disorder. <i>Journal of Psychiatric Research</i> , 2002, 36, 399-406.	3.1	48
475	P300 subcomponents and clinical symptoms in schizophrenia. <i>International Journal of Psychophysiology</i> , 2002, 43, 237-246.	1.0	34
476	Relation between responses to repetitive transcranial magnetic stimulation and partial sleep deprivation in major depression. <i>Journal of Psychiatric Research</i> , 2002, 36, 131-135.	3.1	22
477	Repetitive Transcranial Magnetic Stimulation (rTMS) in Major Depression Relation between Efficacy and Stimulation Intensity. <i>Neuropsychopharmacology</i> , 2002, 27, 638-45.	5.4	98
478	Investigation of a possible diencephalic pathology in schizophrenia. <i>Psychiatry Research - Neuroimaging</i> , 2002, 115, 127-135.	1.8	22
479	Handedness and corpus callosum morphology. <i>Psychiatry Research - Neuroimaging</i> , 2002, 116, 33-42.	1.8	23
480	Human antibodies against amyloid $\beta$ peptide: A potential treatment for Alzheimer's disease. <i>Annals of Neurology</i> , 2002, 52, 253-256.	5.3	152
481	The impact of duration of untreated psychosis and premorbid functioning on outcome of first inpatient treatment in schizophrenic and schizoaffective patients. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2002, 252, 226-231.	3.2	39
482	Value of event-related P300 subcomponents in the clinical diagnosis of mild cognitive impairment and Alzheimer's Disease. <i>Psychophysiology</i> , 2002, 39, 175-181.	2.4	109
483	Switch to Mania After Slow rTMS of the Right Prefrontal Cortex. <i>Journal of Clinical Psychiatry</i> , 2002, 63, 249.	2.2	30
484	Selecting Methodologies for the Evaluation of Differences in Time to Response Between Antidepressants. <i>Journal of Clinical Psychiatry</i> , 2002, 63, 694-699.	2.2	41
485	Partial Response and Nonresponse to Antidepressant Therapy. <i>Journal of Clinical Psychiatry</i> , 2002, 63, 826-837.	2.2	170
486	Evidence for a mitochondrial oxidative phosphorylation defect in brains from patients with schizophrenia. <i>Schizophrenia Research</i> , 2001, 48, 125-136.	2.0	197

#	ARTICLE	IF	CITATIONS
487	Corpus callosum and P300 in schizophrenia. <i>Schizophrenia Research</i> , 2001, 49, 107-119.	2.0	26
488	In-vivo analysis of the human planum temporale (PT): does the definition of PT borders influence the results with regard to cerebral asymmetry and correlation with handedness?. <i>Psychiatry Research - Neuroimaging</i> , 2001, 107, 99-115.	1.8	36
489	Design of Clinical Trials of Antidepressants. <i>CNS Drugs</i> , 2001, 15, 755-764.	5.9	30
490	Viewpoint: Methodological Issues in Psychiatry: Psychiatry as an Empirical Science. <i>World Journal of Biological Psychiatry</i> , 2001, 2, 38-47.	2.6	8
491	Opipramol for the Treatment of Generalized Anxiety Disorder: A Placebo-Controlled Trial Including an Alprazolam-Treated Group. <i>Journal of Clinical Psychopharmacology</i> , 2001, 21, 59-65.	1.4	126
492	Association of Short-Term Response to Haloperidol Treatment With a Polymorphism in the Dopamine D2 Receptor Gene. <i>American Journal of Psychiatry</i> , 2001, 158, 802-804.	7.2	144
493	Prefrontal Cortex Modulation of Mood and Emotionally Induced Facial Expressions. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2001, 13, 206-212.	1.8	31
494	Amisulpride: efficacy in the management of chronic patients with predominant negative symptoms of schizophrenia. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2001, 251, 217-224.	3.2	22
495	Methodological aspects in the assessment of severity of depression by the Hamilton Depression Scale. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2001, 251, 13-20.	3.2	71
496	Deficit states in schizophrenia and their association with the length of illness and gender. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2001, 251, 272-278.	3.2	19
497	Mood-stabilisers reduce the risk of developing antidepressant-induced manic states in acute treatment of bipolar I depressed patients. <i>Journal of Affective Disorders</i> , 2001, 63, 79-83.	4.1	91
498	Are antidepressants less effective in the acute treatment of bipolar I compared to unipolar depression?. <i>Journal of Affective Disorders</i> , 2001, 67, 141-146.	4.1	55
499	Vigabatrin Decreases Cholecystinin-Tetrapeptide (CCK-4) Induced Panic in Healthy Volunteers. <i>Neuropsychopharmacology</i> , 2001, 25, 699-703.	5.4	59
500	Viewpoint: Past, Present and Future of Biological Psychiatry. <i>World Journal of Biological Psychiatry</i> , 2001, 2, 156-158.	2.6	0
501	Association of an Interleukin-1 $\beta$ Genetic Polymorphism With Altered Brain Structure in Patients With Schizophrenia. <i>American Journal of Psychiatry</i> , 2001, 158, 1316-1319.	7.2	110
502	Anxiolytic Effects of Vigabatrin in Panic Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2001, 21, 539-540.	1.4	22
503	Tiagabine Improves Panic and Agoraphobia in Panic Disorder Patients. <i>Journal of Clinical Psychiatry</i> , 2001, 62, 656-657.	2.2	38
504	Definition, Psychopharmacological Basis and Clinical Evaluation of Novel/Atypical Neuroleptics: Methodological Issues and Clinical Consequences. <i>World Journal of Biological Psychiatry</i> , 2000, 1, 75-91.	2.6	48

#	ARTICLE	IF	CITATIONS
505	Translations of Measurements and Scales: Opportunities and Diversities. <i>International Psychogeriatrics</i> , 2000, 12, 391-394.	1.0	11
506	Corpus Callosum Measurement as an <i>in Vivo</i> Indicator for Neocortical Neuronal Integrity, but not White Matter Pathology, in Alzheimer's Disease. <i>Annals of the New York Academy of Sciences</i> , 2000, 903, 470-476.	3.8	15
507	Long-term course of schizophrenic, affective and schizoaffective psychosis: focus on negative symptoms and their impact on global indicators of outcome. <i>Acta Psychiatrica Scandinavica</i> , 2000, 102, 54-57.	4.5	52
508	Re-evaluating the prevalence of and diagnostic composition within the broad clinical spectrum of bipolar disorders. <i>Journal of Affective Disorders</i> , 2000, 59, S5-S30.	4.1	741
509	Quality of life in psychiatry: a systematic contribution to construct validation and the development of the integrative assessment tool "modular system for quality of life". <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2000, 250, 120-132.	3.2	54
510	Platelet Monoamine Oxidase Activity in Alcoholics with and without a Family History of Alcoholism. <i>European Addiction Research</i> , 2000, 6, 57-63.	2.4	11
511	Detection of tau phosphorylated at threonine 231 in cerebrospinal fluid of Alzheimer's disease patients. <i>Neuroscience Letters</i> , 2000, 287, 187-190.	2.1	176
512	State of the Art of Drug Treatment of Schizophrenia and the Future Position of the Novel/Atypical Antipsychotics. <i>World Journal of Biological Psychiatry</i> , 2000, 1, 204-214.	2.6	41
513	Digitized analysis of abnormal hand motor performance in schizophrenic patients. <i>Schizophrenia Research</i> , 2000, 45, 133-143.	2.0	52
514	Impact of duration of symptoms prior to first hospitalization on acute outcome in 998 schizophrenic patients. <i>Schizophrenia Research</i> , 2000, 44, 145-150.	2.0	50
515	Opipramol for the treatment of somatoform disorders results from a placebo-controlled trial. <i>European Neuropsychopharmacology</i> , 2000, 10, 211-217.	0.7	81
516	Social Functioning in Depression. <i>Journal of Clinical Psychiatry</i> , 2000, 61, 268-275.	2.2	464
517	Digitized analysis of handwriting and drawing movements in healthy subjects: methods, results and perspectives. <i>Journal of Neuroscience Methods</i> , 1999, 90, 157-169.	2.5	90
518	In vivo effects of olanzapine on striatal dopamine D <sub>2</sub> /D <sub>3</sub> receptor binding in schizophrenic patients: an iodine-123 iodobenzamide single-photon emission tomography study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1999, 26, 862-868.	6.4	23
519	Discriminant power of combined cerebrospinal fluid I <sub>1</sub> protein and of the soluble interleukin-6 receptor complex in the diagnosis of Alzheimer's disease Preliminary parts of this study have been presented in abstract form at the 6th International Conference on Alzheimer's Disease and Related Disorders, July 18-23, 1998, Amsterdam, The Netherlands and at the 28th Annual Meeting of the Society for Neuroscience, November 7-12, 1998, Los Angeles, CA, USA. <i>Brain Research</i> , 1998, 823, 104-112.	2.2	90
520	Atypical neuroleptics: a new approach in the treatment of negative symptoms. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 1999, 249, S99-S107.	3.2	43
521	Deficit syndromes in schizophrenic patients 15 years after their first hospitalisation: preliminary results of a follow-up study. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 1999, 249, S27-S36.	3.2	35
522	Interleukin-6 and the soluble IL-6 receptor are decreased in cerebrospinal fluid of geriatric patients with major depression: no alteration of soluble gp130. <i>Neuroscience Letters</i> , 1999, 259, 145-148.	2.1	56

#	ARTICLE	IF	CITATIONS
523	Cerebrospinal fluid tau protein shows a better discrimination in young old (<70 years) than in old old patients with Alzheimer's disease compared with controls. <i>Neuroscience Letters</i> , 1999, 277, 21-24.	2.1	62
524	Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia. <i>Psychiatry Research</i> , 1999, 88, 107-117.	3.3	174
525	Repetitive transcranial magnetic stimulation (rTMS) in pharmacotherapy-refractory major depression: comparative study of fast, slow and sham rTMS. <i>Psychiatry Research</i> , 1999, 88, 163-171.	3.3	274
526	P300 subcomponents reflect different aspects of psychopathology in schizophrenia. <i>Biological Psychiatry</i> , 1999, 45, 116-126.	1.3	57
527	Region-Specific Corpus Callosum Atrophy Correlates With the Regional Pattern of Cortical Glucose Metabolism in Alzheimer Disease. <i>Archives of Neurology</i> , 1999, 56, 467.	4.5	52
528	Effectiveness and Safety of Benzodiazepines. <i>Journal of Clinical Psychopharmacology</i> , 1999, 19, 2S-11S.	1.4	50
529	Psychopharmacological therapy and suicide of inpatients with depressive psychoses. <i>Archives of Suicide Research</i> , 1998, 4, 143-155.	2.3	0
530	Decreased soluble interleukin-6 receptor in cerebrospinal fluid of patients with Alzheimer's disease. <i>Brain Research</i> , 1998, 780, 356-359.	2.2	52
531	A review of the reversible MAO-A inhibitor moclobemide in geriatric patients. <i>Human Psychopharmacology</i> , 1998, 13, 43-51.	1.5	4
532	The serotonin syndrome scale: first results on validity. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 1998, 248, 96-103.	3.2	154
533	Risk factors for suicides of inpatients with depressive psychoses. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 1998, 248, 141-147.	3.2	35
534	Antidepressant-associated manifold states in acute treatment of patients with bipolar-I depression. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 1998, 248, 296-300.	3.2	54
535	Markers from event-related potential subcomponents and reaction time for information processing dysfunction in schizophrenia. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 1998, 248, 307-313.	3.2	22
536	Psychopharmacological therapy and suicide of inpatients with depressive psychoses. <i>Archives of Suicide Research</i> , 1998, 4, 143-155.	2.3	4
537	Electroencephalography as a Diagnostic Instrument in Alzheimer's Disease: Reviews and Perspectives. <i>International Psychogeriatrics</i> , 1997, 9, 237-246.	1.0	19
538	The value of selective serotonin re-uptake inhibitors (SSRIs) in the treatment of panic disorder with and without agoraphobia. <i>International Journal of Psychiatry in Clinical Practice</i> , 1997, 1, 59-67.	2.4	5
539	Propentofylline. <i>CNS Drugs</i> , 1997, 8, 265.	5.9	0
540	Interleukin-6 is not altered in cerebrospinal fluid of first-degree relatives and patients with Alzheimer's disease. <i>Neuroscience Letters</i> , 1997, 228, 143-146.	2.1	63

#	ARTICLE	IF	CITATIONS
541	Brofaromine versus imipramine in in-patients with major depression – a controlled trial. <i>Journal of Affective Disorders</i> , 1997, 44, 91-99.	4.1	11
542	Title is missing!. , 1997, 174, 255-259.		95
543	Dipole localization and test-retest reliability of frequency and duration mismatch negativity generator processes. <i>Brain Topography</i> , 1997, 10, 3-8.	1.8	69
544	Dopamine D3 receptor Gly9/Ser9 polymorphism and schizophrenia: no increased frequency of homozygosity in German familial cases. <i>Schizophrenia Research</i> , 1996, 20, 181-186.	2.0	23
545	Drug Treatment of Depression in the 1990s. <i>Drugs</i> , 1996, 52, 625-638.	10.9	61
546	Dementia Treatment: A German Perspective on Psychosocial Aspects and Therapeutic Approaches. <i>International Psychogeriatrics</i> , 1995, 7, 459-470.	1.0	2
547	Involvement of mesial-temporal structures in rapid cycling mood disorders?. <i>Human Psychopharmacology</i> , 1995, 10, 475-480.	1.5	1
548	A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 1995, 245, 45-49.	3.2	139
549	Brofaromine. <i>CNS Drugs</i> , 1995, 3, 1-8.	5.9	9
550	Newer and Older Monoamine Oxidase Inhibitors. <i>CNS Drugs</i> , 1995, 3, 145-158.	5.9	56
551	Biochemical Findings of Negative Symptoms in Schizophrenia and Their Putative Relevance to Pharmacological Treatment. <i>Neuropsychobiology</i> , 1994, 30, 160-172.	1.9	49
552	Plasma concentrations of fluvoxamine and maprotiline in major depression: implications on therapeutic efficacy and side effects. <i>European Neuropsychopharmacology</i> , 1993, 3, 13-21.	0.7	67
553	A serine to glycine substitution at position 9 in the extracellular N-terminal part of the dopamine D3 receptor protein: No role in the genetic predisposition to bipolar affective disorder. <i>Psychiatry Research</i> , 1993, 46, 253-259.	3.3	52
554	Familial Cosegregation of Affective Disorder and Hailey-Hailey Disease. <i>British Journal of Psychiatry</i> , 1993, 163, 109-110.	2.8	21
555	Sicherheit und antidepressive Wirksamkeit von spezifischen Serotonin-Wiederaufnahmehemmern (SSRIs). , 1993, , 163-182.		1
556	Der Verlauf schizophrener Psychosen. , 1986, , .		80